ACB vs. BTMD, CDXC, MDWD, FTLF, MNMD, CGC, USNA, CRON, AMRN, and RANI
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include biote (BTMD), ChromaDex (CDXC), MediWound (MDWD), FitLife Brands (FTLF), Mind Medicine (MindMed) (MNMD), Canopy Growth (CGC), USANA Health Sciences (USNA), Cronos Group (CRON), Amarin (AMRN), and Rani Therapeutics (RANI). These companies are all part of the "medical" sector.
Aurora Cannabis (NASDAQ:ACB) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Aurora Cannabis received 368 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
biote has higher revenue and earnings than Aurora Cannabis. biote is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Aurora Cannabis has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, biote has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 13.9% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
biote has a net margin of 1.79% compared to Aurora Cannabis' net margin of -48.82%. Aurora Cannabis' return on equity of -23.27% beat biote's return on equity.
biote has a consensus price target of $8.11, suggesting a potential upside of 46.92%. Given biote's higher possible upside, analysts plainly believe biote is more favorable than Aurora Cannabis.
In the previous week, Aurora Cannabis had 5 more articles in the media than biote. MarketBeat recorded 7 mentions for Aurora Cannabis and 2 mentions for biote. Aurora Cannabis' average media sentiment score of 0.56 beat biote's score of -0.50 indicating that Aurora Cannabis is being referred to more favorably in the media.
Summary
biote beats Aurora Cannabis on 10 of the 17 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
